Treatment of Endometrial Cancer: Low-Grade Oestrogen Receptor-Positive, Low-Volume or Asymptomatic Advanced or Slowly Growing Recurrent Disease

Clinical Scenario

This protocol applies to low-grade oestrogen receptor-positive endometrial carcinoma presenting as advanced or slowly growing recurrent disease that is low-volume or asymptomatic — a distinct sub-population in which the preferred systemic treatment strategy differs from that used for higher-grade or symptomatic presentations.

Treatment Approach

For this clinical scenario, endocrine therapy is the preferred systemic treatment. The full protocol outlines the specific agents recommended, their supporting evidence grades, and the alternatives considered in this setting — details that go beyond what can be summarised here.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/S1470-2045(25)00167-6

In low-grade oestrogen receptor-positive, low volume or asymptomatic, advanced or slowly growing recurrent tumours, endocrine therapy is the preferred systemic therapy.

In these instances, progestins (medroxyprogesterone or megestrol) are recommended (III, A).

Alternatives include aromatase inhibitors and tamoxifen (IV, C).

View source ↗